Drug Repositioning: New Technologies, Business Models & Strategies for Successful Development
Big Pharma’s 2012 colossal patent cliff looms. Thirteen blockbuster drugs are set to lose US patent protection; costing industry 70% in lost revenues. Furthermore, despite record R&D investment, biopharmaceutical productivity remains in decline. Drug repositioning offers the possibility of breathing new life into pharmaceutical R&D. By recycling drug data, repositioning promises to boost production, accelerate and derisk R&D, and enhance product life-cycle management.